Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Topix

04:10 EDT 22nd August 2018 | BioPortfolio

Here are the most relevant search results for "Topix" found in our extensive news archives from over 250 global news sources.

More Information about Topix on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Topix for you to read. Along with our medical data and news we also list Topix Clinical Trials, which are updated daily. BioPortfolio also has a large database of Topix Companies for you to search.

Showing News Articles 1–25 of 1,900+ from Topix

Wednesday 23rd May 2018

Will Artificial Intelligence Revolutionize Pharma?

Artificial intelligence may be able to improve the drug discovery and approval processes, saving the pharmaceutical industry both time and money. Yet adoption has been slow.

Teva Pharm says FDA to decide on migraine drug on September 16

Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay. JERUSALEM: Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.

UPDATE 1-Teva hopes to launch migraine drug as soon as September

Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay. The debt-ridden company is counting on the drug - fremanezumab - along with Huntington's treatment Austedo, to help it return to growth.

Mylan (MYL) Shares Bought by Alerus Financial NA

Alerus Financial NA increased its stake in Mylan by 126.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 109,314 shares of the company's stock after buying an additional 61,033 shares during the period.

How the marijuana industry will shift as big entities buy in

What does Big Pharma have in mind for cannabis? That question has been on the minds of medical marijuana patients for some time, with many fearing that the price and availability of the healing plant on which they rely for well-being will no longer be attainable. The state of Colorado has already pushed consumers in the direction of store-bought cannabis products by reducing the legal plant count ...

Anchor Capital Advisors LLC Lowers Stake in McKesson

Anchor Capital Advisors LLC reduced its position in McKesson by 1.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 148,416 shares of the company's stock after selling 2,158 shares during the period.

Former Valeant Exec Found Guilty on Charges Related to Kickback Scheme

A Manhattan federal jury found a former executive at Valeant Pharmaceuticals International Inc. guilty of charges that he defrauded the pharmaceutical giant through a multimillion-dollar kickback scheme.

Tuesday 22nd May 2018

San Diego City Council rejects boardwalk scooter ban

The San Diego City Council Tuesday rejected an emergency ordinance that would have banned motorized scooters on boardwalks in Mission Beach, Pacific Beach, Mission Bay and La Jolla. The vehicles have become increasingly common in San Diego since they were introduced in February by scooter-sharing companies Bird and LimeBike.

Victory Capital Management Inc. Boosts Stake in Cardinal Health

Victory Capital Management Inc. lifted its stake in shares of Cardinal Health by 21.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 186,392 shares of the company's stock after buying an additional 32,314 shares during the period.

Cardinal Health: Continuous Business Model Evolution At A Great Price

When investors consider Cardinal Health , they typically immediately think of the large pharmaceutical distribution business that has been at the heart of its DNA for the more than three decades it has been a public company. During that time, shares have typically traded at a discount to the S&P 500 index, as the business comes with very low margins, minimal pricing power, and seemingly low ba...

Death of CDC worker who drowned ruled a suicide

Authorities say the death of a Centers for Disease Control and Prevention employee whose body was found in a river in Atlanta has been ruled a suicide. Fulton County chief medical examiner Dr. Jan Gorniak said Tuesday that Timothy Cunningham's death was a suicide by drowning.

CDC researcher Timothy Cunningham's death ruled a suicide by drowning Source: Cox Media Group

The death of an Atlanta researcher whose body was pulled from the Chattahoochee River has been ruled a suicide by drowning , the Fulton County Medical Examiner said Tuesday. Timothy Cunningham, an epidemiologist with the Centers for Disease Control and Prevention, was reported missing Feb. 14 from his northwest Atlanta home.

KBC Group NV Has $23.48 Million Position in Bristol-Myers Squibb Co

KBC Group NV boosted its holdings in Bristol-Myers Squibb Co by 16.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,225 shares of the biopharmaceutical company's stock after acquiring an additional 51,770 shares during the quarter.

Bristol-Myers Squibb Co (BMY) Shares Sold by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. decreased its stake in Bristol-Myers Squibb Co by 10.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,634 shares of the biopharmaceutical company's stock after selling 3,615 shares during the period.

Rockefeller Capital Management L.P. Takes Position in Bristol-Myers Squibb Co

Rockefeller Capital Management L.P. purchased a new position in shares of Bristol-Myers Squibb Co in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 347,626 shares of the biopharmaceutical company's stock, valued at approximately $21,987,000.

JMP Securities Analysts Give Fortress Biotech (FBIO) a $11.00 Price Target

The firm currently has a "buy" rating on the biopharmaceutical company's stock. JMP Securities' price objective points to a potential upside of 212.50% from the stock's previous close.

Chemists at FAU successfully demonstrate imine hydrogenation with inexpensive main group metal

In future, inexpensive and bio-compatible main group metals could replace expensive and toxic transition metals during catalytic processes. Chemists at Friedrich-Alexander-UniversitA t Erlangen-NA1 4rnberg have now demonstrated that imine hydrogenation is possible using calcium instead of precious metals.

Recent Research Analysts' Ratings Updates for Ovid Therapeutics

They set a "buy" rating and a $20.00 price target on the stock. 5/10/2018 - Ovid Therapeutics was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating.

India's Dr. Reddy's Q4 profit falls about 19 pct, misses estimates

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 19 percent fall in quarterly net profit, missing estimates, hurt by headwinds in the U.S. market. Profit for the quarter ended March 31 came in at 2.72 billion rupees versus 3.38 billion rupees a year earlier, the company said here Net sales fell slightly to 34.46 billion rupees.

Corbus Pharmaceuticals adds two key executives to lead its regulatory and CMC operations

Corbus Pharmaceuticals appoints Robert Discordia, Ph.D., as Vice President, Pharmaceutical Development & Manufacturing, and Ross Lobell as Vice President, Regulatory Affairs.

Mylan (MYL) Stake Lowered by American International Group Inc.

American International Group Inc. decreased its holdings in shares of Mylan by 3.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The fund owned 207,471 shares of the company's stock after selling 6,397 shares during the quarter.

Sirtex in trading halt over developments on CDH takeover offer

Biotech company Sirtex has entered a trading halt ahead of an announcement relating to "material developments" in the $1.9 billion proposal it received from CDH Investments earlier this month. The $US20 billion Chinese-based alternative asset manager made a non-binding, indicative counter offer for Sirtex at $33.60 cash a share on May 4. The CDH offer is subject to due diligence and approval by CD...

Contrasting Cardinal Health

Cardinal Health and Nu Skin Enterprises are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Cardinal Health pays an annual dividend of $1.85 per share and has a dividend yield of 3.5%.

US clings to health coverage gains despite political drama

This screen grab shows the main page of the healthcare.gov website in Washington, on Monday, May 21, 2018. A major government survey finds that the U.S. clung to its health insurance gains last year, a surprise after President Donald Trump's repeated attempts to dismantle "Obamacare."

Monday 21st May 2018

Achillion Pharmaceuticals (ACHN) Upgraded to "Hold" by Barclays

The firm currently has a $5.00 price objective on the biopharmaceutical company's stock. Barclays' target price points to a potential upside of 35.14% from the stock's previous close.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks